New Drug Controls Sickle Cell Disease-Linked Hypertension
University of Maryland School of Medicine
Treatment for lung condition could help patients with SCD control complications from hypertension and kidney damage
Sickle Cell Disease
FDA Approves First Gene Therapies for Sickle Cell Disease
U.S. Food and Drug Administration
The FDA granted the approval of Casgevy to Vertex Pharmaceuticals Inc., and Lyfgenia to Bluebird Bio Inc.
New Transfusion Guidelines Recommend Assessing Patient Comorbidities
Rutgers University
The expert panel developed recommendations to conserve blood supply and prevent transfusion-related illnesses
New Gene Therapy for Sickle Cell Disease Shows Promise in Trials
University of Chicago Medical Center
Trial findings add to growing body of evidence supporting CRISPR-Cas9-led gene therapies for genetic diseases
FDA Approves First Trial Using CRISPR to Correct Sickle Cell Disease Mutation
Lorna Fernandes
The early phase, first-in-human trial aims to correct the sickle mutation in blood stem cells that causes the disease
Personalized Treatment for Sickle Cell Disease
Texas A&M University
New organ-on-a-chip technology could lead to patient-centric, personalized treatment for sickle cell disease